Closing Techniques

Old-school closing tactics — the assumptive close, the puppy dog close, the now-or-never close — are relics of an era when information asymmetry gave salespeople leverage over poorly informed buyers. Today's B2B buyer is well-researched, has likely evaluated competitors, and responds to pressure tactics by disengaging. Manipulation-based closing damages trust and, even when it works, creates customers who feel they were cornered — terrible for retention and referrals. The modern approach to closing starts much earlier in the sales process. A deal that closes easily is one where discovery was thorough, the champion is strong, the business case is solid, the economic buyer is engaged, and the evaluation process was transparent. Closing is not a dramatic final act — it's the natural conclusion of a well-executed sales process. If you're struggling to close, the problem is usually found earlier: incomplete discovery, lack of a champion, weak business case, or a prospect who was never actually qualified. That said, closing does require a clear ask. Many salespeople avoid the explicit ask because they fear rejection. The result is deals that stall — the prospect is interested but hasn't been given a clear path to yes. The closing conversation should be explicit about what the next step is, who needs to take it, and by when. Not "Let me know when you're ready to move forward" but "Based on our conversation, I'd like to propose we schedule a call with your CFO and myself next Thursday to review the business case and confirm the investment. Does that work?" The trial close is a useful technique throughout the sales process — not just at the end. Periodic temperature checks ("Based on what you've seen so far, do you see this fitting your needs?") reveal hidden objections earlier when they're easier to address, and build a cumulative pattern of small yeses that make the final yes feel consistent with the conversation's momentum.

Urgency is real in B2B sales — deals without a compelling reason to move forward will stall indefinitely in the prospect's priority stack. The challenge is creating legitimate urgency rather than manufactured urgency. Manufactured urgency (artificial deadlines, fake discounts, false scarcity) is easily detected by sophisticated buyers and irreparably damages trust when caught. Legitimate urgency comes from consequences of inaction. In MEDDIC terms, you've already quantified the cost of the problem. The closing conversation makes that cost explicit in time terms: "Every month you delay addressing this, the cost to your team is approximately [X]. If you could start implementation by [date], you'd recover that value by [quarter]." This is not pressure — it's helping the prospect make an informed economic decision. Other legitimate urgency mechanisms: implementation timelines (your team has capacity to start your implementation in Q2, but Q3 slots are filling up — this is real if it's true, and a lie if it isn't); business cycle timing (if your prospect has a fiscal year-end or a major product launch that creates a natural deadline for getting your solution in place, that's legitimate urgency); and event-driven triggers (a regulatory deadline, a competitive threat, a planned expansion — any externally driven date creates real urgency). The most powerful closing technique is making the decision path clear and supported. Your champion needs to know exactly what they need to do internally to make the decision happen. Walk through the steps with them: who needs to approve, what paperwork is required, what the implementation kickoff looks like, what success milestones will be tracked. The more clearly the path is illuminated, the less friction exists between a positive decision and a signed contract.